New microbial air sampler addresses continuous monitoring
New ImpactAir ISO-90 microbial air sampler.
The device supports the new EU GMP Annex 1 requirements.
Cherwell Laboratories, specialist suppliers of environmental monitoring and process validation solutions for the pharmaceutical and related industries has launched its latest addition to the ImpactAir microbial air sampler range, which aims to support the new EU GMP Annex 1 requirements for continuous environmental monitoring (EM).
Cherwell, distributors of the ImpactAir range of microbial air samplers from Pinpoint Scientific, will be displaying the prototype of the new ImpactAir ISO-90 Monitoring Platform on their stand. ImpactAir is designed for continuous monitoring in high-grade areas, where in-process sampling of viable particles is often critical. The ImpactAir ISO is a modular system designed to integrate into isolators or RABS, using an external controller and remotely located air mover.
The new ImpactAir ISO model can be designed in almost any orientation using standard or custom-made connections. The ISO-90-Monitoring Head features a chamber for 90mm agar plates and a highly efficient slit to agar sampling method to give highly reliable and consistent results. The low D50 value and ability to sample for long periods makes the ISO-90 ideal for continuous monitoring as demanded by the Annex 1 revision.
Andy Whittard, Managing Director at Cherwell commented, “We are really excited about the latest developments from Pinpoint and feel the ImpactAir ISO-90 will address a key requirement within pharma EM. That is to achieve higher sample volume within grade A environments and minimise risk in these critical zones. Further developments to the ISO-90 range promise to make installation within existing facilities easy.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.